These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 35941029)

  • 21. Allogeneic hematopoietic cell transplantation for adult patients with treatment-related acute myeloid leukemia during first remission: Comparable to de novo acute myeloid leukemia.
    Tang FF; Huang XJ; Zhang XH; Chen H; Chen YH; Han W; Chen Y; Wang FR; Wang Y; Wang JZ; Yan CH; Sun YQ; Mo XD; Liu KY; Xu LP
    Leuk Res; 2016 Aug; 47():8-15. PubMed ID: 27239735
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Post-remission strategies for the prevention of relapse following allogeneic hematopoietic cell transplantation for high-risk acute myeloid leukemia: expert review from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.
    Lee CJ; Savani BN; Mohty M; Gorin NC; Labopin M; Ruggeri A; Schmid C; Baron F; Esteve J; Giebel S; Ciceri F; Nagler A
    Bone Marrow Transplant; 2019 Apr; 54(4):519-530. PubMed ID: 30104717
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Immunosuppressive role of CD11b
    Hyun SY; Na EJ; Jang JE; Chung H; Kim SJ; Kim JS; Kong JH; Shim KY; Lee JI; Min YH; Cheong JW
    Cancer Med; 2020 Oct; 9(19):7007-7017. PubMed ID: 32780544
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Deregulated Expression of Circular RNAs Is Associated with Immune Evasion and Leukemia Relapse after Allogeneic Hematopoietic Stem Cell Transplantation.
    Zhao F; Zhang X; Pei X; Yang D; Han M
    Genes (Basel); 2022 Oct; 13(11):. PubMed ID: 36360223
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Put in a "Ca
    Lewuillon C; Laguillaumie MO; Quesnel B; Idziorek T; Touil Y; Lemonnier L
    Cells; 2022 Feb; 11(3):. PubMed ID: 35159351
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Bone Marrow Microenvironment as a Source of New Drug Targets for the Treatment of Acute Myeloid Leukaemia.
    Skelding KA; Barry DL; Theron DZ; Lincz LF
    Int J Mol Sci; 2022 Dec; 24(1):. PubMed ID: 36614005
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Case Report: Preemptive Treatment With Low-Dose PD-1 Blockade and Azacitidine for Molecular Relapsed Acute Myeloid Leukemia With RUNX1-RUNX1T1 After Allogeneic Hematopoietic Stem Cell Transplantation.
    Tang Y; Zhou Z; Yan H; You Y
    Front Immunol; 2022; 13():810284. PubMed ID: 35185899
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Analysis of risk factors of relapse after allogeneic hematopoietic stem cell transplantation in patients with t (8;21) acute myeloid leukemia].
    Guo WW; Liu X; Pang AM; Zhai WH; Yang DL; Chen X; Ma QL; He Y; Zhang RL; Feng SZ; Han MZ; Jiang EL
    Zhonghua Xue Ye Xue Za Zhi; 2021 Dec; 42(12):998-1004. PubMed ID: 35045670
    [No Abstract]   [Full Text] [Related]  

  • 29. A case of systemic mastocytosis associated with acute myeloid leukemia terminating as aleukemic mast cell leukemia after allogeneic hematopoietic stem cell transplantation.
    Bae MH; Kim HK; Park CJ; Seo EJ; Park SH; Cho YU; Jang S; Chi HS; Lee KH
    Ann Lab Med; 2013 Mar; 33(2):125-9. PubMed ID: 23483057
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Alterations of the bone marrow stromal microenvironment in adult patients with acute myeloid and lymphoblastic leukemias before and after allogeneic hematopoietic stem cell transplantation.
    Shipounova IN; Petinati NA; Bigildeev AE; Drize NJ; Sorokina TV; Kuzmina LA; Parovichnikova EN; Savchenko VG
    Leuk Lymphoma; 2017 Feb; 58(2):408-417. PubMed ID: 27244369
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Exploiting epigenetically mediated changes: Acute myeloid leukemia, leukemia stem cells and the bone marrow microenvironment.
    Kogan AA; Lapidus RG; Baer MR; Rassool FV
    Adv Cancer Res; 2019; 141():213-253. PubMed ID: 30691684
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Natural Killer Immunotherapy for Minimal Residual Disease Eradication Following Allogeneic Hematopoietic Stem Cell Transplantation in Acute Myeloid Leukemia.
    Hattori N; Nakamaki T
    Int J Mol Sci; 2019 Apr; 20(9):. PubMed ID: 31027331
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Measurable residual disease in hematopoietic stem cell transplantation-eligible patients with acute myeloid leukemia: clinical significance and promising therapeutic strategies.
    Gaut D; Mead M
    Leuk Lymphoma; 2021 Jan; 62(1):8-31. PubMed ID: 33138674
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Immunotherapy for acute myeloid leukemia (AML): a potent alternative therapy.
    Acheampong DO; Adokoh CK; Asante DB; Asiamah EA; Barnie PA; Bonsu DOM; Kyei F
    Biomed Pharmacother; 2018 Jan; 97():225-232. PubMed ID: 29091870
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Reversible suppression of T cell function in the bone marrow microenvironment of acute myeloid leukemia.
    Lamble AJ; Kosaka Y; Laderas T; Maffit A; Kaempf A; Brady LK; Wang W; Long N; Saultz JN; Mori M; Soong D; LeFave CV; Huang F; Adams H; Loriaux MM; Tognon CE; Lo P; Tyner JW; Fan G; McWeeney SK; Druker BJ; Lind EF
    Proc Natl Acad Sci U S A; 2020 Jun; 117(25):14331-14341. PubMed ID: 32513686
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Up-regulation of regulatory T cells, CD200 and TIM3 expression in cytogenetically normal acute myeloid leukemia.
    Zahran AM; Mohammed Saleh MF; Sayed MM; Rayan A; Ali AM; Hetta HF
    Cancer Biomark; 2018; 22(3):587-595. PubMed ID: 29843224
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Spontaneous remission in a patient with very late relapse of acute myeloid leukemia 17 years after allogeneic blood stem cell transplantation.
    Rautenberg C; Kaivers J; Germing U; Haas R; Schroeder T; Kobbe G
    Eur J Haematol; 2019 Aug; 103(2):131-133. PubMed ID: 31066931
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Monitoring TIGIT/DNAM-1 and PVR/PVRL2 Immune Checkpoint Expression Levels in Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia.
    Hattori N; Kawaguchi Y; Sasaki Y; Shimada S; Murai S; Abe M; Baba Y; Watanuki M; Fujiwara S; Arai N; Kabasawa N; Tsukamoto H; Uto Y; Yanagisawa K; Saito B; Harada H; Nakamaki T
    Biol Blood Marrow Transplant; 2019 May; 25(5):861-867. PubMed ID: 30639819
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cytomegalovirus Reactivation after Allogeneic Hematopoietic Stem Cell Transplantation is Associated with a Reduced Risk of Relapse in Patients with Acute Myeloid Leukemia Who Survived to Day 100 after Transplantation: The Japan Society for Hematopoietic Cell Transplantation Transplantation-related Complication Working Group.
    Takenaka K; Nishida T; Asano-Mori Y; Oshima K; Ohashi K; Mori T; Kanamori H; Miyamura K; Kato C; Kobayashi N; Uchida N; Nakamae H; Ichinohe T; Morishima Y; Suzuki R; Yamaguchi T; Fukuda T
    Biol Blood Marrow Transplant; 2015 Nov; 21(11):2008-16. PubMed ID: 26211985
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Toll-like Receptor 4, Osteoblasts and Leukemogenesis; the Lesson from Acute Myeloid Leukemia.
    Bruserud Ø; Reikvam H; Brenner AK
    Molecules; 2022 Jan; 27(3):. PubMed ID: 35163998
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.